Colorectal Cancer
Conditions
Keywords
colorectal cancer, Bevacizumab, Oxaliplatin, Irinotecan, 5FU, capecitabine
Brief summary
The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal cancer
Interventions
DRUGBVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1 BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1 BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly
DRUGBVZ+XELOX
BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
Sponsors
Hoffmann-La Roche
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* informed consent signed * Histological or citological adenocarcinoma confirmation carcinoma on the colon or colorectal metastatic or relapsed patients with adenocarcinoma of colon or recto, confirmed histologically with metastatic disease * measurable disease (following RECIST criteria) * ECOG ≤ 2 * older or equal 18 years old * life expectancy superior to 3 months * Adequate or moderate renal function: renal function (Creatinine clearance \> 30mL/min), based on Cockroff - Gault. * Potential fertile women negative pregnancy test in serum or urine, 10 days prior the first study dose given * Use an adequate contraceptive method
Exclusion criteria
* Patients treated previously with Bevacizumab * Non measurable lesion as only disease evidence * Previous chemotherapy treatment for adjuvant or neoadjuvant disease (no metastatic (M0), or immunotherapy active/passive for the advance or metastatic disease. It is permitted the adjuvant or neoadjuvant treatment it is has finished at least 6 months before the initiation of the study drug.If the patient has received an adjuvant treatment previously the patient cannot participate if disease progression has been confirmed during the treatment or on the 6 months later * Prior radiotherapy is allowed if it has not been administered in the target lesions selected for this study, unless progression of said lesions in the irradiated field is documented, and as long as treatment has concluded at least 4 weeks before beginning the study. * Prior surgical treatment of the disease in stage IV is allowed * Functional dependency * Previous serious adverse events or unexpected to fluoropyrimidine treatment and /o patients with proved deficit in dehidropirimidin dehydrogenase (DPD) * Patients classified as weak or fragile * Cardiac concomitant present: Symptomatic auriculoventricular arrhythmia history, and / cardiac arrhythmias requiring medication or peripheral vascular disease, grade II or higher. Furthermore, those patients who have had a myocardial infarction in the year prior to beginning the treatment of the study will be excluded. * History of another neoplastic disease during the last five years, with the exception of cured basal cell carcinoma of the skin and cervical carcinoma in situ. * History or indications of CNS disease in the physical examination. * History of psychiatric disability that the investigator considers clinically significant, which prevents the patient from granting the informed consent or interferes with compliance of taking the oral medication. * Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular disease: CVA/stoke (≤ 6 months prior to randomisation), myocardial infarction (≤ 6 months prior to randomisation), unstable angina, New York Heart Association (NYHA,) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication. * Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medication. * Patients subjected to organ allograft who require immunosuppressive treatment. * Severe, non-cicatrized osseous fractures, wounds or ulcers * Indications of hemorrhagic diathesis or coagulopathy. * Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant diseases. * Any of the following laboratory values: 1. Absolute neutrophil count (ANC) \< 1.5 x 109/l 2. Platelet count \< 100 x 109/l 3. Hemoglobin \< 10 g/dl (it can be transfused to maintain or exceed this level) 4. International Normalized Ratio (INR) \> 1.5 5. Total bilirubin \> 1.5 times the upper limit of normal (ULN) 6. ALAT, ASAT \> 2.5 x ULN or \> 5 x (ULN) in the case of hepatic metastases 7. Alkaline phosphatase \> 2.5 x ULN or \> 5 x ULN in the case of hepatic metastases or \> 10 x ULN in the case of osseous metastases. * Patients subjected to a major surgical procedure, open biopsy or who have had significant traumatic lesions within the 28 days prior to beginning the treatment of the study or in whom it is foreseen that a major surgical procedure will be necessary during the course of the study; fine-needle aspiration within the 7 days prior to beginning the treatment of the study. * Current or recent use (within the 10 days prior to beginning the treatment of the study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents. The use of low doses of warfarin is allowed, with an International Normalized Ratio \[INR\] of \< 1.5. * Daily chronic treatment with high doses of aspirin (\> 325 mg/day) or non-steroid anti-inflammatory medications (which inhibit the platelet function at doses used for treating chronic inflammatory diseases). * Patients who have received any drug or agent/procedure under research, i.e., who have participated in another clinical trial during the 4 weeks prior to beginning the treatment with the medications of the study. * Pregnancy or lactating woman. Woman with reproductive potential unless using an effective method of contraception (Postmenopausal woman must have been amenorrheic during at least 12 months). * Known hypersensitivity to any of the study drugs or excipients of the Bevacizumab or to Chinese hamster ovary cell products or to other recombinant human or humanised antibodies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | 2010-2014 |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | 2010-2014 |
| Objective response rate | 2010-2014 |
| % of patients whose disease becomes resectable | 2010-2014 |
| Adverse events | 2010-2014 |
| Evaluation of KRAS status as a molecular marker | 2010-2014 |
Countries
Spain
Outcome results
None listed